Page last updated: 2024-12-11
trimethyllead
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6327255 |
MeSH ID | M0118185 |
Synonyms (12)
Synonym |
---|
trimethylplumbane |
trimethyl lead |
brn 4123008 |
plumbane, trimethyl- |
lead, trimethyl- |
trimethyllead |
unii-d49dud1v6c |
d49dud1v6c , |
7442-13-9 |
lead, hydrotrimethyl- |
DTXSID5032234 |
zn9 , |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Referring to the low level of 21 micrograms lead per 100 ml blood and regarding the dose-response relations reported in the literature, the results support the hypothesis of a special neurotoxicity of the alkyllead compounds." | ( Neurobehavioral effects of a long-term exposure to tetraalkyllead. Blaszkewicz, M; Kiesswetter, E; Neidhart, B; Seeber, A, ) | 0.13 |
" In contrast, the group administered TML (3/4 LD50) exhibited a late developing antinocioception which became evident 14 days after dosing and persisted throughout the period of testing." | ( Organometal-induced antinociception: a time- and dose-response comparison of triethyl and trimethyl lead and tin. McLamb, RL; Tilson, HA; Walsh, TJ, 1984) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (31.82) | 18.7374 |
1990's | 6 (27.27) | 18.2507 |
2000's | 7 (31.82) | 29.6817 |
2010's | 2 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.04) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |